eCite Digital Repository

Controlling cancer pain: Is morphine the best we can do?


Dietis, ND and Rowbotham, DJ and Lambert, DG, Controlling cancer pain: Is morphine the best we can do?, Trends in anaesthesia and critical care, 1 pp. 227-229. ISSN 2210-8467 (2011) [Substantial Review]

Not available

DOI: doi:10.1016/j.tacc.2011.08.003


Despite the existence of a family of 3 classical and one non-classical opioid receptor, morphine, acting at the MOP (m) receptor remains the gold standard for use in cancer pain. The main thrust of opioid development has been to produce highly selective morphine like molecules but these produce side effects (respiratory depression and arrest, constipation, nausea and vomiting, pruritis and tolerance). Tolerance is particularly troublesome as this leads to increased dosing and more side effects. Laboratory experiments suggest that simultaneous targeting of multiple members of the opioid family may be the way forward. For example disruption of DOP (d) receptor activity reduces morphine tolerance. Rational design and evaluation of non-selective opioids might offer good quality analgesia, reduced side effects and an alternative to morphine.

Item Details

Item Type:Substantial Review
Research Division:Biomedical and Clinical Sciences
Research Group:Pharmacology and pharmaceutical sciences
Research Field:Basic pharmacology
Objective Division:Manufacturing
Objective Group:Human pharmaceutical products
Objective Field:Human pharmaceutical products not elsewhere classified
UTAS Author:Dietis, ND (Dr Nikolas Dietis)
ID Code:80394
Year Published:2011
Deposited By:Pharmacy
Deposited On:2012-10-31
Last Modified:2015-05-15

Repository Staff Only: item control page